<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Current methods of protein detection are insensitive to detecting subtle changes in oncoprotein activation that underlie key <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> signaling processes </plain></SENT>
<SENT sid="1" pm="."><plain>The requirement for large numbers of cells precludes serial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sampling for assessing a response to therapeutics </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we have developed a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes </plain></SENT>
<SENT sid="3" pm="."><plain>Our method can quantify amounts of MYC oncoprotein and B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> protein-2 (BCL2) in Burkitt's and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in <z:chebi fb="0" ids="45783">imatinib</z:chebi>-treated <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogeneous <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with <z:mp ids='MP_0005481'>CML</z:mp> who responded to <z:chebi fb="0" ids="45783">imatinib</z:chebi>; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who were treated with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we have described a new and highly sensitive method for determining oncoprotein expression and phosphorylation in clinical specimens for the development of new therapeutics for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>